NCT03417024 is a clinical trial of Automated Breast Ultrasound in Breast Cancer, sponsored by GE Healthcare.

Who is sponsoring NCT03417024?

NCT03417024 is sponsored by GE Healthcare.

What drugs are being tested in NCT03417024?

Interventions in NCT03417024: Automated Breast Ultrasound, Digital Breast Tomosynthesis.

What condition does NCT03417024 study?

NCT03417024 studies Breast Cancer.

Is NCT03417024 still recruiting?

NCT03417024 is currently terminated. Last updated 9 September 2019.

Are results published for NCT03417024?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-09-09 · How we verify

NCT03417024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Automated Breast Ultrasound Case Collection Registry

Terminated Results posted Last updated 9 September 2019

What this trial tests

trial testing Automated Breast Ultrasound in Breast Cancer in 13 participants. Terminated before completion.

Timeline

12 July 2018

Primary endpoint
25 January 2019

25 January 2019

Quick facts

Lead sponsor	GE Healthcare
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	13
Start date	12 July 2018
Primary completion	25 January 2019
Estimated completion	25 January 2019
Sites	1 location across United States

Drugs / interventions tested

Automated Breast Ultrasound
Digital Breast Tomosynthesis

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

GE Healthcare — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Type of Exams Performed Per Patient Secondary · Up to 6 years

ABUS

Group	Value	95% CI
All Subjects	11

DBT

Group	Value	95% CI
All Subjects	12

Breast Cancer Status Secondary · Up to 6 years

Initial Diagnosis (Cancer)

Group	Value	95% CI
All Subjects	0

Initial Diagnosis (Non-Cancer)

Group	Value	95% CI
All Subjects	4

Sponsor's own description

The contribution of automated breast ultrasound (ABUS) to the screening pathway for breast cancer is not fully understood. This prospective study aims to collect longitudinal data in women with dense breasts undergoing ABUS as a supplement to digital breast tomosynthesis (DBT). The data are intended for use in future research on the value and effectiveness of ABUS in routine clinical care. Data will be collected from eligible women who have been prescribed or have completed DBT and ABUS, screening within a 30-day window. Radiologist evaluations and, when performed, outcomes of biopsy and/or laboratory testing will be recorded. Subjects will be followed for breast cancer status and results of any diagnostic breast exams and/or treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Automated Breast Ultrasound

Trials testing the same drug.

NCT05408260 — A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer · NA · completed

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other GE Healthcare trials

Trials by the same sponsor.

NCT07472491 — A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients · Phase 2, PHASE3 · recruiting
NCT07394140 — NMT EasyFit Sensor and Cable · NA · not yet recruiting
NCT07024472 — NIBP Cuff Comparison Study · completed
NCT06835647 — Maternal Fetal Device Performance Twins · NA · recruiting
NCT06639828 — Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03417024 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GE Healthcare
Last refreshed: 9 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03417024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing